Hos abataceptbehandlede patienter i studie II og III sås en statistisk signifikant forbedring i ACR 20 - respons versus placebo efter administration af første dosis (dag 15), og denne forbedring forblev signifikant igennem hele studiet.
In abatacept-treated patients in Studies II and III, statistically significant improvement in the ACR 20 response versus placebo was observed after administration of the first dose (day 15), and this improvement remained significant for the duration of the studies.